diff --git a/domains/health/glp1-behavioral-support-market-stratifies-by-physical-integration-with-atoms-to-bits-companies-profitable-and-behavioral-only-companies-bankrupt.md b/domains/health/glp1-behavioral-support-market-stratifies-by-physical-integration-with-atoms-to-bits-companies-profitable-and-behavioral-only-companies-bankrupt.md
index c228bc7a2..204f81863 100644
--- a/domains/health/glp1-behavioral-support-market-stratifies-by-physical-integration-with-atoms-to-bits-companies-profitable-and-behavioral-only-companies-bankrupt.md
+++ b/domains/health/glp1-behavioral-support-market-stratifies-by-physical-integration-with-atoms-to-bits-companies-profitable-and-behavioral-only-companies-bankrupt.md
@@ -52,3 +52,10 @@ WeightWatchers' post-bankruptcy (May 2025) strategy shows selective CGM deployme
 **Source:** Noom press releases + Pharmaceutical Commerce, December 2025
 
 Noom's December 2025 'Proactive Health Microdose GLP-1Rx' program ($149/month) combines microdosed GLP-1 with at-home biomarker testing every four months, representing a distinct atoms-to-bits integration strategy from Omada's continuous CGM monitoring. This periodic biomarker testing approach (quarterly) vs. continuous monitoring (daily) represents two different physical-to-digital integration strategies with different cost/adherence tradeoffs. Noom achieved $100M revenue run-rate within four months of launching GLP-1 programs in September 2024, demonstrating that periodic biomarker testing can be commercially viable as a physical integration layer.
+
+
+## Supporting Evidence
+
+**Source:** HIT Consultant Dec 2025, WW Clinic review 2026
+
+WeightWatchers Med+ program (launched December 2025, 7 months post-bankruptcy) excludes CGM integration for general obesity/GLP-1 program despite having CGM for diabetes tier. WW chose behavioral depth + prescribing quality over physical data integration. This creates a direct market test: WW (behavioral-only for general obesity) vs Omada (CGM-integrated, profitable 2025 IPO). WW's 21% weight loss claim relies on internal study (n=3,250), not externally validated. The one-time metabolic lab work is a single physical data capture, not continuous monitoring like Omada's CGM.
diff --git a/inbox/queue/2025-12-17-weight-watchers-med-plus-glp1-program-2026-no-cgm-integration.md b/inbox/archive/health/2025-12-17-weight-watchers-med-plus-glp1-program-2026-no-cgm-integration.md
similarity index 98%
rename from inbox/queue/2025-12-17-weight-watchers-med-plus-glp1-program-2026-no-cgm-integration.md
rename to inbox/archive/health/2025-12-17-weight-watchers-med-plus-glp1-program-2026-no-cgm-integration.md
index f4ee834e6..395362368 100644
--- a/inbox/queue/2025-12-17-weight-watchers-med-plus-glp1-program-2026-no-cgm-integration.md
+++ b/inbox/archive/health/2025-12-17-weight-watchers-med-plus-glp1-program-2026-no-cgm-integration.md
@@ -7,10 +7,13 @@ date: 2025-12-17
 domain: health
 secondary_domains: []
 format: thread
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-01
 priority: medium
 tags: [WeightWatchers, GLP-1, CGM, atoms-to-bits, Belief4, obesity-management, behavioral-support, telehealth]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content